In This Article:
NEW YORK, NY / ACCESSWIRE / August 8, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Ardelyx Inc. (NASDAQ:ARDX)
CONTACT JAKUBOWITZ ABOUT ARDX:
https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=18322&from=1
Class Period : August 6, 2020 - July 19, 2021
Lead Plaintiff Deadline : September 28, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
Concho Resources Inc. (NYSE:CXO)
CONTACT JAKUBOWITZ ABOUT CXO:
https://claimyourloss.com/securities/concho-resources-inc-loss-submission-form/?id=18322&from=1
Class Period : February 21, 2018 - July 31, 2019
Lead Plaintiff Deadline : September 28, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the well spacing at Dominator was aggressive and highly risky, and premised on no reasonable basis to believe it would work as intended; (2) Concho's practice of implementing tighter well spacing was not relegated to a handful of "tests" and therefore more widespread than the market was led to believe; (3) it was known or recklessly disregarded that any measures to mitigate well spacing risks were non-existent and or/impossible; (4) these risks had manifested during the Class Period, causing underground well interference and permanently decreasing production, forcing the Company to scale back production targets and adopt more conservative spacing measures in its other projects; (5) it would take multiple quarters to unwind the impacts of the widespread well spacing failure; and (6) as a result of the foregoing, the Company's public statements were materially false and misleading at all relevant times.